For U.S. healthcare professionals only

Tailor FVIII Prophylaxis to Fit Their Lives

Management of hemophilia A has evolved beyond a “one-size-fits-all” approach to one that is multidimensional and aligned with each specific patient’s goals and lifestyle.1,2

Some patient characteristics that play into the individualization of FVIII prophylaxis include:

(Click icons to learn more)

Scale icon depicting the age and weight of a patient can impact FVIII prophylaxis dosage.

Age & Weight

Pulse graph icon from the pharmacokinetics (PK) tool.

Pharmacokinetic (PK) response

Trophy cup icon depicting how important a treatment goal is for a hemophilia patient.

Treatment goals

Single leg icon depicting how physical activity and lifestyle should be considered for a hemophilia A patient.

Physical activity & lifestyle

DNA icon depicting the bleeding phenotype.

Bleeding phenotype

Calendar icon depicting how important adherence to the treatment regimen is.

Adherence to treatment regimen

The patients weight and age determines the dose of FVIII treatment.1,2

Age & Weight

The patients weight and age determines the dose of FVIII treatment.1,2

Pharmacokinetic (PK) response

Understanding each patient's peak and trough levels, determined by pharmacokinetic analysis, can help in tailoring that patient's dosing regimen around their lifestyle and activities.1

Treatment goals

Your patients' goals—from feeling comfortable attending college to slowing joint damage—can inform their prophylaxis regimen.1

Physical activity & lifestyle

Understanding a patient's physical activity and lifestyle can help determine an appropriate dosing schedule to help achieve adequate coverage.1

Bleeding phenotype

Bleeding pattern and arthropathy can vary significantly among patients with FVIII levels lower than 1%, including those with identical mutations in the F8 gene.1

Adherence to treatment regimen

It's important to work with your patient to develop a treatment plan that meets their individual needs. Some of the common obstacles to full adherence include denial, lack of patient/parent/family commitment, and the time-consuming nature of prophylaxis. On the other hand, encouraging patients to establish a routine can improve adherence.1

GET THE MOST OUT OF THEIR INDIVIDUAL ROUTINE

The measurability of FVIII can help optimize a patient’s treatment regimen by allowing it to be tailored to the parameters of patients’ individual PK curves.1,3

Maintaining optimal factor coverage levels is important during situations with higher bleeding risk. Physical activity (≥50% factor levels), surgery (50%–80%), and trauma/high-risk surgery (>80%) all require level adjustment to reduce the risk of bleeds.3,4

Clock icon depicting how important Factor VIII treatment routine is.

PK-GUIDED PROPHYLAXIS UNIQUE TO YOUR PATIENTS

Using PK-guided prophylaxis with FVIII can help you gain deeper insight into peak and trough levels to better target bleeding patterns. Many patients may respond to a PK-guided routine because their chosen lifestyle and activities play a role in their treatment.5

But remember: this type of treatment requires strong commitment from your patients, as it means more intense monitoring, plus the flexibility to change as their lifestyle does.5

Pulse graph icon from the pharmacokinetics (PK) tool.

References:

1. Valentino LA. Considerations in individualizing prophylaxis in patients with haemophilia A. Haemophilia. 2014;20(5):607-615. 2. Petrini P, Valentino LA, Gringeri A, Re WM, Ewenstein B. Individualizing prophylaxis in hemophilia: a review. Expert Rev Hematol. 2015;8(2):237-246. 3. Iorio A, Iserman E, Blanchette V, et al. Target plasma factor levels for personalized treatment in haemophilia: a Delphi consensus statement. Haemophilia. 2017;23(3):e170-e179. 4. Broderick CR, Herbert RD, Latimer J, et al. Association between physical activity and risk of bleeding in children with hemophilia. JAMA. 2012;308(14):1452-1459 5. Hazendonk HC, van Moort I, Mathôt RA, et al. Setting the stage for individualized therapy in hemophilia: what role can pharmacokinetics play? Blood Rev. 2018;32(4):265-271.

Are you a U.S. healthcare professional?

You are being directed to WhyFactor8.com/hcp. The information on this website is intended for U.S. healthcare professionals only

No, I am not an HCP